Carbetocin heat stability study
In April, the Journal of Peptide Science published a paper on Development and stability of a heat‐stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle‐income countries.
The study contains the stability data for heat stable carbetocin, developed by Ferring Pharmaceuticals as tested under ICH Zone IV conditions (hot and humid). The results of the testing showed that heat stable carbetocin maintained ≥95% purity for a minimum of 3 years at 30°C, 6 months at 40°C, 3 months at 50°C and 1 month at 60°C. In addition, the heat‐stable carbetocin formulation was not sensitive to freezing or light.
The development of a highly stable uterotonic has long been sought to overcome the quality concerns with oxytocin that result from the drug’s susceptibility to degradation when exposed to heat. Oxytocin is the uterotonic currently recommended by the World Health Organization as the preferred uterotonic for prevention of PPH due to its efficacy and safety profile.
The full article is available online at: https://onlinelibrary.wiley.com/doi/abs/10.1002/psc.3082
Uterotonics network meta-analysis
A second major study on uterotonics has been published by the Cochrane Library. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis is a statistical comparison of all uterotonic agents that seeks to rank each drug and combination of drugs used for prevention of postpartum haemorrhage in terms of effectiveness in PPH and side-effects. The study challenges current recommendations, however judgement should be withheld until the study is updated to include the results of two major uterotonics studies that will be published later this year. The full article is available online at: http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD011689.pub2/abstract